Hawkary Pharmaceutical Company# Pharmaceutical Import Profile — Iraq (DGFT 2022–2026)

Name: Hawkary Pharmaceutical Company# Pharmaceutical Import Records from India — 3 Products, $1.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Hawkary Pharmaceutical Company# — Pharmaceutical Importer Profile (2026) | 3 Products, $1.6M Trade | TransData Nexus

Hawkary Pharmaceutical Company#

Pharmaceutical Importer · Iraq · Antihistamines & Allergy Focus · $1.6M Total Trade · DGFT Verified

Hawkary Pharmaceutical Company# is a pharmaceutical importer based in Iraq with a total trade value of $1.6M across 3 products in 3 therapeutic categories. Based on 33 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Hawkary Pharmaceutical Company# sources from 1 verified Indian supplier, with Micro Labs Limited accounting for 100.0% of imports.

Hawkary Pharmaceutical Company# — Import Portfolio & Supplier Network

Hawkary Pharmaceutical Company# import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Hawkary Pharmaceutical Company#?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Micro Labs Limited	$4.5M	155	100.0%

Hawkary Pharmaceutical Company# sources from 1 verified Indian supplier across 86 distinct formulations. The sourcing is highly concentrated — Micro Labs Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Hawkary Pharmaceutical Company# Import?

Formulation	Value	Ships
Pulmoxyl 250 dry syrup (amoxicillin	$823.9K	25
Azilide dry syrup (azithromycin for	$295.1K	6
Olan-10 (olanzapine 10MG tablets )	$150.0K	3
Hipril - a (amlodipine 5MG & lisinopril5mg tablets) (3x10s) - tax invoice no: 712202959 dt;	$135.6K	3
Hipril - a (amlodipine 5MG + lisinopril5mg tablets) (3x10s) - tax invoice no: 712203004 dt;	$132.5K	3
Dawnex capsules (fluoxetine capsules	$102.2K	3
Supixime dry syrup 100MG/5ML (cefixime for oral suspension USP 100MG) x 60ML - tax invoice no: 707202088 dt	$101.1K	3
Supixime dry syrup 100MG/5ML (cefixime for oral suspension USP 100MG) x 60ML - tax invoice no: 707202087 dt	$100.6K	3
Nebilong 5 (nebivolol hydrochloride	$100.0K	2
Supixime-100 dry syrup (cefixime for	$100.0K	2
Hipril - a (amlodipine lisinopril	$100.0K	2
Metronidazole 500 (metronidazole	$87.6K	2
Divon gel (diclofenac diethylamine	$79.9K	2
Apivas 5 ( (apixaban tablets 5MG) ) ( 6x10's ) ( qty- 4867.000 )	$75.0K	2
Hipril - a (amlodipine & lisinopril tablets) (3x10s) - tax invoice no: 712202849dt	$69.2K	3

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Chlorpheniramine	Antihistamines & Allergy	$700.0K	14	1.5%	6
2	Lisinopril	Cardiovascular	$619.4K	13	1.0%	8
3	Azithromycin	Antibiotics	$300.0K	6	0.2%	2

Hawkary Pharmaceutical Company# imports 3 pharmaceutical products across 3 categories into Iraq totaling $1.6M.

Hawkary Pharmaceutical Company# — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Hawkary Pharmaceutical Company, established in 1992, is a leading pharmaceutical distribution firm headquartered in Erbil, Kurdistan Region of Iraq. Over the years, it has secured a significant share in the Iraqi market, positioning itself among the top five fastest-growing local pharmaceutical distribution companies in the country. The company specializes in the distribution and marketing of pharmaceutical products, continually expanding its portfolio to meet the evolving needs of the growing pharmaceutical market.

Under the leadership of Dr. Muhammed Ismail Seyan, who serves as the Chairman and Acting CEO, Hawkary has demonstrated a commitment to excellence and quality in its operations. The company has proactively integrated an Enterprise Resource Planning (ERP) system to enhance the efficiency of its functional units by consolidating all business functions into a single database. This integration facilitates seamless information flow across the organization and ensures timely delivery of quality products and services to its customers.

2Distribution Network

Hawkary Pharmaceutical Company boasts an extensive distribution network that spans the entire Iraqi territory, including major cities such as Erbil, Baghdad, Basra, Karbala, Tikrit, Sulaymaniyah, Duhok, Mosul, and Kirkuk. This comprehensive coverage enables the company to effectively serve a diverse clientele across the nation. The company's logistics capabilities are further enhanced by its adherence to European and US-FDA guidelines of Good Distribution Practice (GDP), ensuring that medical products are distributed with the highest quality assurance standards.

3Industry Role

In Iraq's pharmaceutical supply chain, Hawkary Pharmaceutical Company functions primarily as a wholesaler and distributor. By sourcing a wide array of pharmaceutical products, including those from international markets, the company plays a pivotal role in ensuring the availability of essential medications throughout Iraq. Its extensive distribution network and commitment to quality make it a key player in the country's healthcare sector.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Hawkary Pharmaceutical Company#

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Hawkary Pharmaceutical Company's sourcing strategy reveals a high degree of concentration, with a total import value of $1.6 million USD from India over 33 shipments, primarily from a single supplier, MICRO LABS LIMITED. This indicates a strategic choice to maintain a focused supplier relationship, potentially leveraging benefits such as favorable pricing, consistent product quality, and reliable supply chains. However, this single-source dependency also introduces risks, including vulnerability to supply disruptions or changes in supplier terms. The shipment data suggests a stable and ongoing relationship with MICRO LABS LIMITED, as evidenced by the consistent import activity over the period.

2Supply Chain Resilience

The resilience of Hawkary Pharmaceutical Company's supply chain is closely tied to its reliance on a single supplier for a significant portion of its imports. While this focused approach may streamline operations and strengthen supplier relationships, it also exposes the company to potential risks such as supply chain disruptions, geopolitical issues, or changes in supplier policies. The company's adherence to international standards, including Good Distribution Practice (GDP), and its proactive integration of an Enterprise Resource Planning (ERP) system, suggest a commitment to maintaining high-quality standards and operational efficiency. However, the lack of publicly available information regarding backup suppliers or alternative sourcing strategies indicates a potential area for improvement in enhancing supply chain resilience.

Importing Pharmaceuticals into Iraq — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Iraq

1Regulatory Authority & Framework

In Iraq, the Ministry of Health (MOH), through the Iraq Drug Regulatory Authority (IDRA), oversees the regulation of pharmaceutical imports, ensuring that all medicines meet safety, efficacy, and quality standards. The IDRA is responsible for granting marketing authorizations, which are typically time-limited (commonly five years) and renewable with updated data. The regulatory framework mandates that all medicines, including generics, undergo a registration process that includes evidence of Good Manufacturing Practice (GMP) compliance. For generics, this process is abbreviated and bioequivalence-driven, while biologics and biosimilars require comparability packages. Promotion of pharmaceutical products is tightly controlled, with strict rules on interactions with healthcare professionals.

2Import Licensing & GMP

Import licensing in Iraq requires that all pharmaceutical products, including generics, be registered with the IDRA, demonstrating compliance with GMP standards. The IDRA recognizes GMP certifications from reputable international bodies, such as the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). To distribute pharmaceutical products in Iraq, companies must obtain wholesale distribution authorization from the MOH, ensuring that all operations adhere to the country's regulatory requirements.

Hawkary Pharmaceutical Company# — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Hawkary Pharmaceutical Company's product strategy focuses on key therapeutic areas, including antihistamines and allergy medications, cardiovascular drugs, and antibiotics. The company's imports from India predominantly consist of chlorpheniramine (an antihistamine), lisinopril (a cardiovascular drug), and azithromycin (an antibiotic), indicating a strategic emphasis on these therapeutic categories. This focus aligns with the market demand for treatments addressing common health concerns in Iraq, such as allergies, cardiovascular diseases, and infectious diseases. By concentrating on these areas, Hawkary aims to meet the prevalent healthcare needs of the Iraqi population.

2Sourcing Profile

Hawkary Pharmaceutical Company's sourcing strategy is centered on importing finished pharmaceutical formulations from India, with a particular emphasis on generic drugs. The company's portfolio includes a diverse range of formulations, with 86 unique products imported from a single supplier, MICRO LABS LIMITED. This approach allows Hawkary to offer a wide array of pharmaceutical products to the Iraqi market, ensuring availability and accessibility of essential medications. The focus on generic drugs enables the company to provide cost-effective treatment options to patients, aligning with the growing demand for affordable healthcare solutions in Iraq.

Market Positioning

Seller's Guide — How to Become a Supplier to Hawkary Pharmaceutical Company#

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Hawkary Pharmaceutical Company, particularly in therapeutic areas where Hawkary's current sourcing is limited or where there is a growing demand in the Iraqi market. By offering high-quality products that align with Hawkary's existing portfolio and addressing any gaps in their current sourcing, new suppliers can establish a mutually beneficial partnership. Additionally, with the Iraqi government's recent decision to reduce the import of certain locally produced medicines, there may be an increased demand for imported pharmaceutical products, presenting an opportune time for new suppliers to enter the market.

2Requirements & Qualifications

Indian exporters seeking to supply Hawkary Pharmaceutical Company and the Iraqi market must ensure that their products comply with the regulatory requirements set forth by the Ministry of Health and the Iraq Drug Regulatory Authority. This includes obtaining marketing authorizations, demonstrating compliance with Good Manufacturing Practice (GMP) standards recognized by international bodies such as the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), and adhering to labeling requirements, including the use of the Arabic language. Additionally, products must undergo batch testing and stability studies to confirm their safety, efficacy, and quality.

Frequently Asked Questions — Hawkary Pharmaceutical Company#

What products does Hawkary Pharmaceutical Company# import from India?

Hawkary Pharmaceutical Company# imports 3 pharmaceutical products across 3 categories. Top imports: Chlorpheniramine ($700.0K), Lisinopril ($619.4K), Azithromycin ($300.0K).

Who supplies pharmaceuticals to Hawkary Pharmaceutical Company# from India?

Hawkary Pharmaceutical Company# sources from 1 verified Indian suppliers. The primary supplier is Micro Labs Limited (100.0% of imports, $4.5M).

What is Hawkary Pharmaceutical Company#'s total pharmaceutical import value?

Hawkary Pharmaceutical Company#'s total pharmaceutical import value from India is $1.6M, based on 33 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Hawkary Pharmaceutical Company# focus on?

Hawkary Pharmaceutical Company# imports across 3 categories. The largest: Antihistamines & Allergy (43.2%), Cardiovascular (38.2%), Antibiotics (18.5%).

Get Full Hawkary Pharmaceutical Company# Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.